These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8630883)

  • 1. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.
    Storlie JA; Buckner JC; Wiseman GA; Burch PA; Hartmann LC; Richardson RL
    Cancer; 1995 Jul; 76(1):96-100. PubMed ID: 8630883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.
    Morioka M; Kobayashi T; Furukawa Y; Jo Y; Shinkai M; Matsuki T; Yamamoto T; Tanaka H
    Urol Int; 2002; 68(1):10-5. PubMed ID: 11803262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Scher HI; Kelly WK
    J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer.
    Nishiyama T; Terunuma M
    Urol Int; 2000; 65(1):28-31. PubMed ID: 10965298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma.
    Nishimura K; Nonomura N; Yasunaga Y; Takaha N; Inoue H; Sugao H; Yamaguchi S; Ukimura O; Miki T; Okuyama A
    Cancer; 2000 Dec; 89(12):2570-6. PubMed ID: 11135218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
    Di Silverio F; Sciarra A
    J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
    J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients.
    Saika T; Kusaka N; Tsushima T; Yamato T; Ohashi T; Suyama B; Arata R; Nasu Y; Kumon H;
    Int J Urol; 2001 Jun; 8(6):290-4. PubMed ID: 11389744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer.
    Khandwala HM; Vassilopoulou-Sellin R; Logethetis CJ; Friend KE
    Endocr Pract; 2001; 7(1):11-5. PubMed ID: 11250762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pattern of prostate-specific antigen responses following hormonal therapy in Thai men with bone metastatic prostate cancer.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 2003 Sep; 86(9):809-15. PubMed ID: 14649965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
    Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
    Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
    Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.
    Venkitaraman R; Thomas K; Huddart RA; Horwich A; Dearnaley DP; Parker CC
    BJU Int; 2008 Feb; 101(4):440-3. PubMed ID: 17941935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
    Kashiwabara T; Suda S
    BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Int J Urol; 2007 Feb; 14(2):123-7. PubMed ID: 17302568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modular therapy approach in metastatic castration-refractory prostate cancer.
    Walter B; Rogenhofer S; Vogelhuber M; Berand A; Wieland WF; Andreesen R; Reichle A
    World J Urol; 2010 Dec; 28(6):745-50. PubMed ID: 20490506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.